|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-3-1
|
|
pubmed:abstractText |
To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Nitriles,
http://linkedlifedata.com/resource/pubmed/chemical/Placebos,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Triazoles,
http://linkedlifedata.com/resource/pubmed/chemical/lapatinib,
http://linkedlifedata.com/resource/pubmed/chemical/letrozole
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1549-490X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
122-9
|
|
pubmed:meshHeading |
pubmed-meshheading:20156908-Aged,
pubmed-meshheading:20156908-Aged, 80 and over,
pubmed-meshheading:20156908-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20156908-Breast Neoplasms,
pubmed-meshheading:20156908-Disease-Free Survival,
pubmed-meshheading:20156908-Double-Blind Method,
pubmed-meshheading:20156908-Drug Synergism,
pubmed-meshheading:20156908-Female,
pubmed-meshheading:20156908-Humans,
pubmed-meshheading:20156908-Middle Aged,
pubmed-meshheading:20156908-Nitriles,
pubmed-meshheading:20156908-Placebos,
pubmed-meshheading:20156908-Postmenopause,
pubmed-meshheading:20156908-Quinazolines,
pubmed-meshheading:20156908-Receptor, erbB-2,
pubmed-meshheading:20156908-Receptors, Estrogen,
pubmed-meshheading:20156908-Receptors, Progesterone,
pubmed-meshheading:20156908-Treatment Outcome,
pubmed-meshheading:20156908-Triazoles
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
|
|
pubmed:affiliation |
The West Clinic, Memphis, Tennessee, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
